Citigroup
KAPA

Citigroup’s Kairos Pharma KAPA Stock Holding History

Citigroup’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$6 – 6352
2026
Q1 		$6 Buy
+10
New +$7 ﹤0.01% 5770
2025
Q3 		– Sell
-5,499
Closed -$3.9K – 6370
2025
Q2 		$3.9K Buy
+5,499
New +$4K ﹤0.01% 5305

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup's KAPA Position: Q2 2026 in Review

Citigroup sold out of Kairos Pharma (KAPA) in Q2 2026, closing a stake of 10 shares — an estimated $6 sold.

Citigroup first reported a position in KAPA in Q2 2025 and held it in 2 quarters. The position peaked at $3.9K in Q2 2025. 9 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Citigroup reported no remaining Kairos Pharma position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 10 Kairos Pharma shares in Q2 2026, an estimated $6.
  • Citigroup first reported a position in Kairos Pharma in Q2 2025 and held it in 2 quarters.
  • Citigroup's Kairos Pharma position peaked at $3.9K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.